Copyright (c) 2018 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
A Mild and Efficient Copper-Mediated N-Arylation of 6-Azauracil with Corresponding Boronic Acids and their Antibacterial Activity
Corresponding Author(s) : Nareshvarma Seelam
Asian Journal of Chemistry,
Vol. 30 No. 11 (2018): Vol 30 Issue 11
Abstract
A convenient synthetic strategy is reported for the synthesis of N-arylated 6-azauracil through Chan-Lam cross-coupling. A variety of N-arylated 6-azauracil derivatives were synthesized in moderate to good yields by cross-coupling of 6-azauracil with arylboronic acids in the presence of Cu(OAc)2 and pyridine. However the arylation position is confirmed in the case of 2-(3,5-dichlorophenyl)-1,2,4-triazine- 3,5(2H,4H)-dione (3a), by preparing the compound in a traditional method and compared the chemical shift of the NH proton at N-3 position. Further, the synthesized compounds were screened for their antibacterial activity using agar well diffusion method. The results revealed that most of the synthesized moieties possessing promising therapeutic nature.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- R.E. Handschumacher, P. Calabresi, A.D. Welch, V. Bono, H. Fallon and E. Frei, Cancer Chemother. Rep., 21, 1 (1962).
- T.R. Walters, R.J.A. Aur, K. Hernandez, T. Vietti and D. Pinkel, Cancer, 29, 1057 (1972); https://doi.org/10.1002/1097-0142(197204)29:4<1057::AIDCNCR2820290455>3.0.CO;2-Q.
- B. Rada and D. Blaskovic, Acta Virol., 10, 1 (1966).
- D. Falke and B. Rada, Acta Virol., 14, 115 (1970).
- I. Alexeeva, L. Palchikovskaya, A. Shalamay, L. Nosach, V. Zhovnovataya, O. Povnitsa and N. Dyachenko, Acta Biochim. Polon., 47, 95 (2000).
- Y. Kabbaj, H.B. Lazrek, J.L. Barascut and J.L. Imbach, Nucleos. Nucl. Nucl. Acids, 24, 161 (2005); https://doi.org/10.1081/NCN-55695.
- P. Calabresi and R.W. Turner, Ann. Intern. Med., 64, 352 (1966); https://doi.org/10.7326/0003-4819-64-2-352.
- R. Gunther, Wien. Med. Wochenschr., 117, 985 (1967).
- R.C. Deconti and P. Calabresi, Ann. Intern. Med., 73, 575 (1970); https://doi.org/10.7326/0003-4819-73-4-575.
- B.L. Mylari, M.W. Miller, H.L. Howes, S. Figdor, J.E. Lynch and R.C. Koch, J. Med. Chem., 20, 475 (1977); https://doi.org/10.1021/jm00214a003.
- M.W. Miller, B.L. Mylari, H.L. Howes, J.E. Lynch, M.J. Lynch and R.C. Koch, J. Med. Chem., 22, 1483 (1979); https://doi.org/10.1021/jm00198a010.
- J.W. St Geme and H.L. Martin, Infect. Immun., 11, 915 (1975).
- K.A. Steffenhagen, B.C. Easterday and G.J. Galasso, J. Infect. Dis., 133, 603 (1976); https://doi.org/10.1093/infdis/133.6.603.
- J.J. Li, L.H. Mitchell and R.L. Dow, Bioorg. Med. Chem. Lett., 20, 306 (2010); https://doi.org/10.1016/j.bmcl.2009.10.109.
- O. Vanparijs, L. Hermans, L. Van der Flaes, K. Vlaminck and R. Marsboom, Tijdschr. Diergeneeskd., 113, 190 (1988).
- J. Slouka, Monatsh. Chem., 96, 134 (1965); https://doi.org/10.1007/BF00912302.
- E. Riguet, B. Campo, A. Gibelin and K. Mhalla, Novel Triazinedione Derivatives as GABA-β receptor Modulators, WO2008056257 A2 (2008).
- I. Leroy, E. Dupont-Passelaigue, K. Valeille, Y. Rival and D. Junquero, Derivatives of Triazines and Uracils, Their Preparation and Their Application in Human Therapeutics, WO2010006962 A1 (2010).
- Z. Rankovic, J. Cai, X. Fradera, M. Dempster, A. Mistry, A. Mitchell, C. Long, E. Hamilton, A. King, S. Boucharens, C. Jamieson, J. Gillespie, I. Cumming, J. Uitdehaag and M.V. Zeeland, Bioorg. Med. Chem. Lett., 20, 1488 (2010); https://doi.org/10.1016/j.bmcl.2010.01.116.
- P.Y.S. Lam, C.G. Clark, S. Saubern, J. Adams, M.P. Winters, D.M.T. Chan and A. Combs, Tetrahedron Lett., 39, 2941 (1998); https://doi.org/10.1016/S0040-4039(98)00504-8.
- D.M.T. Chan, K.L. Monaco, R.P. Wang and M.P. Winters, Tetrahedron Lett., 39, 2933 (1998); https://doi.org/10.1016/S0040-4039(98)00503-6.
- J.W. Mcfarland, C.B. Cooper and D.M. Newcomb, J. Med. Chem., 34, 1908 (1991); https://doi.org/10.1021/jm00110a023.
- M.W. Miller, 2-Phenyl-as-triazine-3,5(2H,4H)diones, US Patent 3912723 A (1975).
- M.W. Miller, B.L. Mylari, H.L. Howes, S.K. Figdor, M.J. Lynch, J.E. Lynch and R.C. Koch, J. Med. Chem., 23, 1083 (1980); https://doi.org/10.1021/jm00184a005.
- E. Shivarani, R. Parameswar, V. Harinadhababu and Y.S. Ranganath, Int. J. Pharm. Sci., 4, 424 (2012).
References
R.E. Handschumacher, P. Calabresi, A.D. Welch, V. Bono, H. Fallon and E. Frei, Cancer Chemother. Rep., 21, 1 (1962).
T.R. Walters, R.J.A. Aur, K. Hernandez, T. Vietti and D. Pinkel, Cancer, 29, 1057 (1972); https://doi.org/10.1002/1097-0142(197204)29:4<1057::AIDCNCR2820290455>3.0.CO;2-Q.
B. Rada and D. Blaskovic, Acta Virol., 10, 1 (1966).
D. Falke and B. Rada, Acta Virol., 14, 115 (1970).
I. Alexeeva, L. Palchikovskaya, A. Shalamay, L. Nosach, V. Zhovnovataya, O. Povnitsa and N. Dyachenko, Acta Biochim. Polon., 47, 95 (2000).
Y. Kabbaj, H.B. Lazrek, J.L. Barascut and J.L. Imbach, Nucleos. Nucl. Nucl. Acids, 24, 161 (2005); https://doi.org/10.1081/NCN-55695.
P. Calabresi and R.W. Turner, Ann. Intern. Med., 64, 352 (1966); https://doi.org/10.7326/0003-4819-64-2-352.
R. Gunther, Wien. Med. Wochenschr., 117, 985 (1967).
R.C. Deconti and P. Calabresi, Ann. Intern. Med., 73, 575 (1970); https://doi.org/10.7326/0003-4819-73-4-575.
B.L. Mylari, M.W. Miller, H.L. Howes, S. Figdor, J.E. Lynch and R.C. Koch, J. Med. Chem., 20, 475 (1977); https://doi.org/10.1021/jm00214a003.
M.W. Miller, B.L. Mylari, H.L. Howes, J.E. Lynch, M.J. Lynch and R.C. Koch, J. Med. Chem., 22, 1483 (1979); https://doi.org/10.1021/jm00198a010.
J.W. St Geme and H.L. Martin, Infect. Immun., 11, 915 (1975).
K.A. Steffenhagen, B.C. Easterday and G.J. Galasso, J. Infect. Dis., 133, 603 (1976); https://doi.org/10.1093/infdis/133.6.603.
J.J. Li, L.H. Mitchell and R.L. Dow, Bioorg. Med. Chem. Lett., 20, 306 (2010); https://doi.org/10.1016/j.bmcl.2009.10.109.
O. Vanparijs, L. Hermans, L. Van der Flaes, K. Vlaminck and R. Marsboom, Tijdschr. Diergeneeskd., 113, 190 (1988).
J. Slouka, Monatsh. Chem., 96, 134 (1965); https://doi.org/10.1007/BF00912302.
E. Riguet, B. Campo, A. Gibelin and K. Mhalla, Novel Triazinedione Derivatives as GABA-β receptor Modulators, WO2008056257 A2 (2008).
I. Leroy, E. Dupont-Passelaigue, K. Valeille, Y. Rival and D. Junquero, Derivatives of Triazines and Uracils, Their Preparation and Their Application in Human Therapeutics, WO2010006962 A1 (2010).
Z. Rankovic, J. Cai, X. Fradera, M. Dempster, A. Mistry, A. Mitchell, C. Long, E. Hamilton, A. King, S. Boucharens, C. Jamieson, J. Gillespie, I. Cumming, J. Uitdehaag and M.V. Zeeland, Bioorg. Med. Chem. Lett., 20, 1488 (2010); https://doi.org/10.1016/j.bmcl.2010.01.116.
P.Y.S. Lam, C.G. Clark, S. Saubern, J. Adams, M.P. Winters, D.M.T. Chan and A. Combs, Tetrahedron Lett., 39, 2941 (1998); https://doi.org/10.1016/S0040-4039(98)00504-8.
D.M.T. Chan, K.L. Monaco, R.P. Wang and M.P. Winters, Tetrahedron Lett., 39, 2933 (1998); https://doi.org/10.1016/S0040-4039(98)00503-6.
J.W. Mcfarland, C.B. Cooper and D.M. Newcomb, J. Med. Chem., 34, 1908 (1991); https://doi.org/10.1021/jm00110a023.
M.W. Miller, 2-Phenyl-as-triazine-3,5(2H,4H)diones, US Patent 3912723 A (1975).
M.W. Miller, B.L. Mylari, H.L. Howes, S.K. Figdor, M.J. Lynch, J.E. Lynch and R.C. Koch, J. Med. Chem., 23, 1083 (1980); https://doi.org/10.1021/jm00184a005.
E. Shivarani, R. Parameswar, V. Harinadhababu and Y.S. Ranganath, Int. J. Pharm. Sci., 4, 424 (2012).